Drug Trial Radar · NCT07822646
A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Oct 12, 2026
Primary completion
Apr 12, 2029
Study completion Dec 20, 2030
Sponsor
- Lead sponsor
- Chinese PLA General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Epithelial ovarian cancer is the most lethal gynecologic malignancy, and most patients eventually relapse and develop resistance to available therapies. Immune checkpoint inhibitors have shown limited overall efficacy in recurrent ovarian cancer, partly because of its immunosuppressive tumor microenvironment. Manganese (Mn2+) can activate the cGAS-STING pathway and may enhance antitumor immunity and the therapeutic effects of PD-1 blockade combined with chemotherapy. Following encouraging findings from an early-phase study, a randomized, single-blind, placebo-controlled phase II trial showed that the addition of manganese chloride to anti-PD-1 antibody, nab-paclitaxel, and cisplatin improved clinical outcomes compared with placebo, with an overall manageable safety profile. Based on these findings, this phase III trial is designed to confirm the efficacy and further evaluate the safety of Mn2+-primed immunochemotherapy in patients with advanced ovarian cancer.
Conditions
- Ovarian Cancer
Interventions
Manganese ChlorideDrug
Administered by inhalation at 0.4mg/kg twice per week in the first 3-week cycle, and then inhaled 0.4mg/kg twice in the first week of each 3-week cycle thereafter
Nab-paclitaxelDrug
Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)
Platinum chemotherapyDrug
Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve \[AUC\] 4-6 mg/ mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)
Anti-PD-1 antibodyDrug
Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)
PlaceboDrug
Administered by inhalation twice per week in the first 3-week cycle, and then inhaled twice in the first week of each 3-week cycle thereafter
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: 12 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Department of Obstetrics and Gynecology, Seventh Medical Center, Chinese PLA General Hospital
Beijing, Beijing Municipality, China · Recruiting
Department of Bio-therapeutic, First Medical Center, Chinese PLA General Hospital
Beijing, Beijing Municipality, China · Recruiting
Department of Obstetrics and Gynecology, First Medical Center, Chinese PLA General Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University International Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Department of Obstetrics and Gynecology, North China University of Science and Technology Affiliated Hospital
Tangshan, Hebei, China · Not yet recruiting
Department of Gynecologic Oncology, Shanxi Province Cancer Hospital
Taiyuan, Shanxi, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.